Eli Lilly (LLY)
1,437.29
+5.00 (0.35%)
NYSE · Last Trade: Nov 12th, 1:49 AM EST
News & Press Releases
JPMorgan Predicted Strong Wegovy Pill Sales (and Was Right). Is Novo Nordisk Stock a Buy Now?fool.com
Novo Nordisk lived up to expectations for its Wegovy pill in the third quarter, but it still has more work ahead.
Via The Motley Fool · November 11, 2026
Eli Lilly Just Raised Its 2026 Sales Forecast to as Much as $92 Billion. But Is Viking Therapeutics the Next Big Obesity Winner?fool.com
These drugmakers offer very different risk-reward profiles.
Via The Motley Fool · November 11, 2026
Which Is the Better Buy: iShares’ Pharma ETF IHE or First Trust’s Biotech Fund FBT?fool.com
iShares offers lower fees and smoother returns, while First Trust provides concentrated biotech exposure with higher growth potential.
Via The Motley Fool · November 11, 2026
S&P 500 After-Hours Movers: MNST, RDDT Among Gainers; VEEV, LLY Among Losers in Latest Sessionchartmill.com
Via Chartmill · November 11, 2026
Johnson & Johnson vs. Eli Lilly: Which Healthcare Giant's Stock Is a Better Buy for 2027?fool.com
Eli Lilly's sales jumped 44.7% last year, while Johnson & Johnson's steadier profile raises a different question for cautious portfolios.
Via The Motley Fool · November 11, 2026
A Billionaire Investor Links Cancer Treatment and Wireless Technology as AI Pharmaceutical Testing Gains Ground
DALLAS, Texas, November 11, 2026 ImmunityBio (NASDAQ: IBRX), VivoSim Labs (NASDAQ: VIVS), PDS Biotechnology (NASDAQ: PDSB) and Peraso (NASDAQ: PRSO) present distinct developments for investors following cancer treatments, predictive toxicology and advanced wireless communications. Recent commercial results, financing transactions and an upcoming earnings release provide specific reasons to monitor these companies. Dr. Patrick Soon-Shiong connects ImmunityBio, PDS Biotech and Peraso through leadership and/or investment, while VivoSim offers a separate drug-development story tied to human tissue testing and Eli Lilly milestones.
Via AB Newswire · November 11, 2026
My Forever Portfolio: 4 Spectacular Stocks You Can Buy Now and Never Sellfool.com
It takes a slightly different mindset when you're investing for a longer time horizon.
Via The Motley Fool · November 11, 2026
Eli Lilly vs Novo Nordisk: What's the Better GLP-1 Stock to Buy?fool.com
These stocks have been going in different directions over the past year, but that trend may not necessarily continue.
Via The Motley Fool · November 10, 2026
Hims & Hers: 3 Key Takeaways for Long-Term Investorsfool.com
Management is betting that a lighter marketing push now sets Hims & Hers up for the January weight-loss surge, but it's unclear whether lost subscribers will return.
Via The Motley Fool · November 10, 2026
This Growth ETF Has Crushed the S&P 500 Since 2004. Here's Why It's Still a Buy.fool.com
The upside outweighs the inevitable volatility.
Via The Motley Fool · November 10, 2026
Gilead Sciences Stock Hits a New All-Time High: Is it Still a Good Buy?fool.com
The healthcare stock has soared past the S&P 500 this year as its results have been strong in recent quarters.
Via The Motley Fool · November 10, 2026
Want to Escape the AI Sell-Off? This ETF Offers a Surprising Alternativemarketbeat.com
As tech stocks sell off, the ProShares S&P 500 ex-Technology ETF (SPXT) offers reduced AI exposure, but its mega-cap holdings, light liquidity, and trailing returns temper its appeal.
Via MarketBeat · November 9, 2026
Gabelli Releases Agenda for 8th Annual Healthcare Symposium
PALM BEACH, Florida, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Gabelli today released the agenda for its 8th Annual Healthcare Symposium to be held this Friday, November 13 in conjunction with Columbia Business School at the Paley Center for Media in New York. The symposium will bring together leading companies and organizations from across the healthcare ecosystem, with an emphasis on industry dynamics, current trends, and business fundamentals.
By Gabelli Funds · Via GlobeNewswire · November 9, 2026
Eli Lilly Is Now Worth Nearly 9 Novo Nordisks. Here's How the Gap Got So Wide.fool.com
The companies are competing in the weight loss drug market.
Via The Motley Fool · November 9, 2026
New Independent Research Hub Launches for Eloralintide, Lilly’s Investigational Amylin Agonist
Eloralintide-Peptide.com brings Phase 2 and Phase 3 trial data, comparisons with semaglutide, tirzepatide, retatrutide and cagrilintide, and sourcing checks together in one place
Via Press Release Distribution Service · November 9, 2026
3 Super Growth Stocks to Buy Hand Over Fist If the Stock Market Crashesfool.com
One of these stocks is up 265% over the past year -- and its shares don't seem wildly overvalued, either.
Via The Motley Fool · November 8, 2026
Novo Nordisk's Wegovy Pill Has Topped 5 Million Prescriptions. Is the Stock a Buy Now?fool.com
Novo Nordisk is looking to build a volume-driven business, but the successful launch of the Wegovy pill is just the first step.
Via The Motley Fool · November 8, 2026
Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trialsfool.com
Everyone is talking about the GLP-1 battle between Eli Lilly and Novo Nordisk, but Pfizer wants in on the fight, too.
Via The Motley Fool · November 7, 2026
Eli Lilly Just Raised Its 2026 Revenue Forecast by $5.5 Billion. Is the Stock Still a Buy?fool.com
The stock is expensive, but the potential market for GLP-1 drugs is likely much larger than forecast.
Via The Motley Fool · November 7, 2026
IYH and XBI: Two Distinct Paths to Investing in Healthcarefool.com
XBI delivered stronger 1-year returns at 45%, but IYH's diversified portfolio weathered volatility far better, with a maximum drawdown of just 17.9% versus 53.2%.
Via The Motley Fool · November 7, 2026
Certified PEP MEX Expands Its Reach in Mexico With Two New Research Peptide Websites
Péptidos Verificados brings the full catalog together for online purchase, while Péptido Retatrutida focuses on a molecule as it rounds out its Phase 3 program.
Via Press Release Distribution Service · November 7, 2026
Eli Lilly Is Much More Than a Weight-Loss Drug Company. Here's the Evidencefool.com
Eli Lilly could thrive even as competition in the weight-loss market intensifies.
Via The Motley Fool · November 6, 2026
Hims & Hers Surges On 'Surprising And Inevitable' Deal With Eli Lillyinvestors.com
Hims & Hers Health inked a deal with Eli Lilly on Friday to sell the company's obesity drugs.
Via Investor's Business Daily · November 6, 2026
Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
Eli Lilly and Company (NYSE: LLY) and Hims & Hers Health, Inc. (NYSE: HIMS) today announced an agreement to help expand access to Zepbound (tirzepatide) and Foundayo (orforglipron). Through the agreement, eligible patients who receive a prescription from a licensed provider on the Hims & Hers platform will access the same self-pay prices available to any patient without leaving the Hims & Hers platform.
By Hims & Hers · Via Business Wire · November 6, 2026
2 Growth Stocks to Buy in November Without Any Hesitationfool.com
They have both outperformed the broader equity market over the long run.
Via The Motley Fool · November 5, 2026